SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001479290-16-000049
Filing Date
2016-08-05
Accepted
2016-08-05 16:08:26
Documents
62
Period of Report
2016-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvncq21610q.htm 10-Q 1140005
2 EXHIBIT 31.1 rvnc-q216exhibit311.htm EX-31.1 13581
3 EXHIBIT 31.2 rvnc-q216exhibit312.htm EX-31.2 13478
4 EXHIBIT 32.1 rvnc-q216exhibit321.htm EX-32.1 6241
5 EXHIBIT 32.2 rvnc-q216exhibit322.htm EX-32.2 6266
  Complete submission text file 0001479290-16-000049.txt   4673620

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT rvnc-20160630.xml EX-101.INS 940868
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20160630.xsd EX-101.SCH 35348
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20160630_cal.xml EX-101.CAL 65670
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20160630_def.xml EX-101.DEF 112227
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20160630_lab.xml EX-101.LAB 412672
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20160630_pre.xml EX-101.PRE 243661
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 161811225
SIC: 2834 Pharmaceutical Preparations